{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:10:12Z","timestamp":1791591012746,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2016YFC1000707"],"award-info":[{"award-number":["2016YFC1000707"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","seizure-journal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.seizure.2020.03.018","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T07:35:19Z","timestamp":1587972919000},"page":"20-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9040-1542","authenticated-orcid":false,"given":"Wen","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Qian-Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Mei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2020.03.018_bib0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2020.03.018_bib0010","series-title":"Tuberous sclerosis complex","author":"Gomez","year":"1999"},{"key":"10.1016\/j.seizure.2020.03.018_bib0015","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.03.018_bib0020","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.03.018_bib0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","article-title":"Neurological and neuropsychiatric aspects of tuberous sclerosis complex","volume":"14","author":"Curatolo","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2020.03.018_bib0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","article-title":"Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist","volume":"52","author":"de Vries","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2020.03.018_bib0035","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2020.03.018_bib0040","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.seizure.2020.03.018_bib0045","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaad.2015.07.018","article-title":"Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus","volume":"73","author":"Nathan","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.seizure.2020.03.018_bib0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","article-title":"Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial","volume":"153","author":"Wataya-Kaneda","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.seizure.2020.03.018_bib0055","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2020.03.018_bib0060","article-title":"Efficacy and safety of adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex (TSC) in children under 6 years of age: results from the phase 3 EXIST-3 extension phase","volume":"82","author":"Franz","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2020.03.018_bib0065","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S2352-4642(18)30099-3","article-title":"Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial","volume":"2","author":"Curatolo","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.seizure.2020.03.018_bib0070","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.S9.007","article-title":"Efficacy and safety of everolimus based on prior and concomitant antiepileptic drugs in patients with tuberous sclerosis complex (TSC)-associated treatment-refractory seizures: a subanalysis of the phase 3 EXIST-3 study","volume":"90","author":"Franz","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2020.03.018_bib0075","article-title":"Outcomes among adult patients with tuberous sclerosis complex (TSC)-associated treatment-refractory seizures treated with adjunctive everolimus: final analysis of the Exist-3 study","volume":"59","author":"Wiemer-Kruel","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.03.018_bib0080","first-page":"S296","article-title":"Long-term safety, rollover study of adjunctive everolimus in patients with tuberous sclerosis complex (TSC)-associated treatment-refractory seizures who continue to benefit from everolimus treatment after completion of EXIST-3","volume":"59","author":"Yapici","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.03.018_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.braindev.2018.07.003","article-title":"Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan","volume":"41","author":"Mizuguchi","year":"2019","journal-title":"Brain Dev"},{"key":"10.1016\/j.seizure.2020.03.018_bib0090","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1212\/WNL.0000000000003077","article-title":"Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial","volume":"87","author":"Overwater","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2020.03.018_bib0095","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2020.03.018_bib0100","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.seizure.2020.03.018_bib0105","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/archdermatol.2011.254","article-title":"Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol","volume":"147","author":"DeKlotz","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.seizure.2020.03.018_bib0110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00246-016-1528-y","article-title":"Accelerated cardiac rhabdomyoma regression with everolimus in infants with tuberous sclerosis complex","volume":"38","author":"Aw","year":"2017","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.seizure.2020.03.018_bib0115","doi-asserted-by":"crossref","DOI":"10.1177\/0883073808324535","article-title":"Rapamycin reduces seizure frequency in tuberous sclerosis complex","volume":"24","author":"Muncy","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2020.03.018_bib0120","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1212\/WNL.0000000000003703","article-title":"Letter re: sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial","volume":"88","author":"Zou","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2020.03.018_bib0125","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/01.wnl.0000345365.92821.86","article-title":"Cyst-like tubers are associated with TSC2 and epilepsy in tuberous sclerosis complex","volume":"72","author":"Chu-Shore","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2020.03.018_bib0130","first-page":"2021","article-title":"Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options","volume":"10","author":"Wang","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.seizure.2020.03.018_bib0135","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study","volume":"15","author":"Franz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seizure.2020.03.018_bib0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2020.03.018_bib0145","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMc1800352","article-title":"Maternal sirolimus therapy for fetal cardiac rhabdomyomas","volume":"378","author":"Barnes","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2020.03.018_bib0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yebeh.2017.02.007","article-title":"Influence of seizures on early development in tuberous sclerosis complex","volume":"70","author":"Capal","year":"2017","journal-title":"Epilepsy Behav"}],"updated-by":[{"DOI":"10.1016\/j.seizure.2020.08.026","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000}}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120301059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120301059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T15:25:41Z","timestamp":1722785141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131120301059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":30,"alternative-id":["S1059131120301059"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2020.03.018","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2020.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}